Apimeds Pharmaceuticals US, Inc.

SEC 10-K Item 1C cybersecurity disclosure describing the registrant's cybersecurity risk management framework, board oversight, and third-party risk processes. The filing explicitly states the registrant has not experienced any cybersecurity incidents that have materially affected or are reasonably likely to materially affect its business strategy, results of operations, or financial condition. No specific breach, threat actor, affected individuals, or data types are disclosed.